| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$44.90 |
| 52 Week High | NT$102.50 |
| 52 Week Low | NT$43.60 |
| Beta | 0.73 |
| 1 Month Change | -8.55% |
| 3 Month Change | -14.15% |
| 1 Year Change | -51.09% |
| 3 Year Change | -30.82% |
| 5 Year Change | 80.32% |
| Change since IPO | -40.13% |
Recent News & Updates
Recent updates
Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04
A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06Shareholder Returns
| 1762 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -1.8% | -1.5% | -0.6% |
| 1Y | -51.1% | 8.8% | 29.2% |
Return vs Industry: 1762 underperformed the TW Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: 1762 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 1762 volatility | |
|---|---|
| 1762 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 1762 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1762's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | n/a | Chung-Hsin Huang | www.ccsb.com.tw |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Fundamentals Summary
| 1762 fundamental statistics | |
|---|---|
| Market cap | NT$3.48b |
| Earnings (TTM) | NT$264.91m |
| Revenue (TTM) | NT$2.09b |
13.1x
P/E Ratio1.7x
P/S RatioIs 1762 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1762 income statement (TTM) | |
|---|---|
| Revenue | NT$2.09b |
| Cost of Revenue | NT$1.33b |
| Gross Profit | NT$757.31m |
| Other Expenses | NT$492.40m |
| Earnings | NT$264.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.42 |
| Gross Margin | 36.30% |
| Net Profit Margin | 12.70% |
| Debt/Equity Ratio | 35.8% |
How did 1762 perform over the long term?
See historical performance and comparison